CBD: Narcotic substance or a novel food product?
CBD is at the forefront of pharmacology. So why has the European Commission changed its recommended status to “Narcotic”? Read on to find out more.
Ensuring regulatory compliance for Medical Cannabis
Here, Evolve Ltd’s Managing Director, Christopher Busuttil Delbridge, takes us progressively deeper into what it takes to ensure regulatory compliance for Medical Cannabis.
COVID is shifting the conversation about the medical application of CBD
Hannah Deacon, co-founder of Maple Tree Consultancy, explores how COVID is elevating and shaping the medical application of CBD.
A comprehensive guide to CBD in the UK
Here, Professor Mike Barnes discusses and answers some key questions about the world of CBD in the UK.
Antimicrobial resistance: The next big pandemic?
Josep Figueras and Anna Sagan from the European Observatory on Health Systems and Policies focus here on antimicrobial resistance and ponder whether or not this could be the next big pandemic.
Ensuring a high and reproducible quality of medicinal cannabis
Renata Mala, PharmD, Chairman of Purely Plant GmbH, underlines the importance of ensuring high and reproducible quality when it comes to medicinal cannabis.
MHL Series B equity financing and global CPG partnerships
Here, we learn how Mile High Labs, a leading processor of hemp-derived cannabinoids, have raised Series B equity financing and are preparing for global CPG partnerships.
The import of medical cannabis: Germany and the Netherlands
Kathleen Denoodt continues to enlighten us on the subject of medical cannabis, particularly imports to Germany and the Netherlands.
Stop drug testing and start impairment testing
A new public health app by DRUID® measures factors to give an overall score of impairment, evolving the classic idea of drug testing.
Finding new antibiotics: The genome way
Professor Tilmann Weber discusses how microbial genomics helps to find the next generation of antibiotics in the race against antimicrobial resistance.
What is CBD and how does it work?
Savage Cabbage Ltd offer their expertise to explain what cannabidiol (CBD) is and how it works: Read on to find out their perspective.
The European Commission’s ‘pause’ on CBD novel food applications
Associate, David Hardstaff and Partner, John Binns at BCL Solicitors LLP, explain here how cannabis wonder child takes a knock in light of the European Commission’s ‘pause’ on CBD novel food applications mean for this booming industry.
Chronic pain diseases and medical cannabis
Janosch Kratz discusses the importance of medical cannabis for chronic pain diseases.
EUMCA: Limit of 0.2% THC in CBD products should not change
Chair of the European Medicinal Cannabis Association (EUMCA) issues warning that raising limit for THC in CBD to 0.3% will risk patient safety.
How are different types of medical cannabis working for different diseases?
Dr David Moorhouse, General Neurologist, discusses the way that different diseases respond to different types of medical cannabis.
How cannabinoids can be used as pain medicine
Dr Daniela Tonucci, a consultant for over 10 years, talks us through the use of cannabinoids as pain medicine.
The EUMCA: Pioneering access to medicinal cannabis
Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.
Expanding the portfolio of rigorous cannabinoid research with new funding opportunities
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.
Greenheart CBD: A green crop from seed to shelf
Here, we learn how about a different kind of green crop that grows in Ireland and the journey of that from seed to shelf as part of the Greenheart CBD story.
Attracting major investors: GreenLight on the international stage
In the last six months GreenLight Medicines has successfully out-licenced leads from its research, branching out internationally and attracting major investors.
